A US governmental advisory committee is critically looking at inhaled type of insulin which is designed to aid millions of diabetes sufferers who currently depend on injecting to control blood sugar.
The main concern with regards to the drug is its long-term effects on the lungs and whether it is safe and effective for smokers or those who have lung disease, so says documents released by the US Food and Drug Administration.
The inhaled insulin is called Exubera and could help diabetics who do not want to inject. The insulin is being developed by Pfizer, Sanofi-Aventis and Nektar Therapeutics.
The FDA was to consider today whether to recommend the drug to government regulators for approval. The FDA usually follows the recommendations of its advisory committees, but is not required to.
